Corautus Genetics Merges With VIA Following VEGF-2 Gene Therapy Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Principal focus of the newly formed company will be VIA’s cardiovascular pipeline, VIA exec tells “The Pink Sheet” DAILY.